Trial reportFrontiers in immunology2018
Immune-Phenotyping and Transcriptomic Profiling of Peripheral Blood Mononuclear Cells From Patients With Breast Cancer: Identification of a 3 Gene Signature Which Predicts Relapse of Triple Negative Breast Cancer.
Trial report in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04770272 (An Adaptive Randomized Neoadjuvant Two Arm Trial in Triple-negative Breast Cancer Comparing a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy), which is not on this map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Adaptive Randomized Neoadjuvant Two Arm Trial in Triple-negative Breast Cancer Comparing a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy (neoMono)
Who cites it
42 citing papers in PubMed, 77 citations in OpenAlex.
- A Phase I/II Study of Ibrutinib Plus Trastuzumab in HER2-Positive Metastatic Breast Cancer.Cancer medicine · 2026Trial
- Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.Nature communications · 2024Trial
- The effect of resiquimod (a Toll-like receptor-7/8 agonist) on the balance between pro-inflammatory and anti-inflammatory cytokines in breast cancer patients.Discover oncology · 2026Article
- SOX9 and TNFAIP3 dysregulation in HCV-associated HCC after DAA therapy: insights into post-viral oncogenic memory.Infectious agents and cancer · 2026Article
- PAM50 Intrinsic Subtypes and Immunity Status in Prognosis of Triple-Negative Breast Cancer: A Retrospective Cohort Study.Cancers · 2025Article
- Circulating immune cells exhibit distinct traits linked to metastatic burden in breast cancer.Breast cancer research : BCR · 2025Article
- Role of MRE11 in DNA damage repair pathway dynamics and its diagnostic and prognostic significance in hereditary breast and ovarian cancer.BMC cancer · 2025Article
- Triple-negative breast cancer modifies the systemic immune landscape and alters neutrophil functionality.NPJ breast cancer · 2025Article
- Transcriptomic profiling of PBMCs from mammary tumor dogs reveals two distinct immune states.American journal of cancer research · 2025Article
- Monocyte subsets in breast cancer patients under treatment with aromatase inhibitor and mucin-1 cancer vaccine.Journal of translational medicine · 2024Article
- Review
- Peripheral immunophenotyping reveals lymphocyte stimulation in healthy women living with hereditary breast and ovarian cancer syndrome.iScience · 2024Article
- Atypical memory B cells increase in the peripheral blood of patients with breast cancer regardless of lymph node involvement.BMC immunology · 2024Article
- Effectiveness of Chinese Herbal Medicine as a Complementary Treatment for Neutropenia Prevention and Immunity Modulation During Chemotherapy in Patients With Breast Cancer: Protocol for a Real-World Pragmatic Clinical Trial.JMIR research protocols · 2024Article
- The effects of aging, sex, and tumor burden on the peripheral blood immune cell profile and absolute counts.Journal of Cancer · 2024Article
- The impact of cryopreservation on cytokine secretion and polyfunctionality in human PBMCs: a comparative study.Frontiers in immunology · 2024Article
- Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.medRxiv : the preprint server for health sciences · 2023Article
- FAT4 expression in peripheral blood mononuclear cells is associated with prognosis and immune cell infiltration in hepatocellular carcinoma.Scientific reports · 2023Article
- Blood-Based mRNA Tests as Emerging Diagnostic Tools for Personalised Medicine in Breast Cancer.Cancers · 2023Review
- Prognostic value of various immune cells and Immunoscore in triple-negative breast cancer.Frontiers in immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.